Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans
- PMID: 7562419
- DOI: 10.1002/jps.2600840619
Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans
Abstract
The disposition-decomposition analysis (DDA) methodology enables isolation of the overall elimination and distribution effects in pharmacokinetics and facilitates analysis which focuses on drug elimination kinetics and does not require a specific structured modeling of drug distribution processes. A computer algorithm enables a curve fitting and a kinetic estimation by integration of the convolution type integrodifferential equation in the DDA. The approach is demonstrated in an analysis of the nonlinear disposition kinetics of erythropoietin (Epo) in 10 healthy, adult human subjects who each received 10, 100, and 500 U/kg i.v. bolus doses of Epo. The nonlinearity is analyzed according to a Michaelis-Menten type nonlinear elimination function, considering simultaneous fitting to the data from all three doses in each subject. The simultaneous fittings produced estimates of the Michaelis-Menten parameters (mean, % cv) Vm (901 mU/mL/h, 19.4%) and km (4814 mU/mL, 24.6%). A linear clearance parameter is defined as the asymptotic clearance value approached when the drug level decreases toward zero. The degree of nonlinearity reached from various dosings was quantified in terms of a clearance ratio which is defined as the ratio between the linear clearance and the clearance estimated for the maximum drug concentration encountered at the given dose level. The subjects showed very little nonlinearity at the 10 U/kg dosing with a mean clearance ratio of 1.07 (2.1% CV) A statistically significant increase in the degree of nonlinearity was observed in the Epo elimination kinetics as the dosing level was increased to 100 and 500 U/kg, reaching clearance ratios of 1.66 (14% CV) and 4.33 (27% CV), respectively. A zero value for the global elimination rate parameter in all 30 dosings indicates that Epo's elimination is entirely accounted for by nonlinear pathway(s).
Similar articles
-
A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans.Biopharm Drug Dispos. 1999 May;20(4):217-23. doi: 10.1002/(sici)1099-081x(199905)20:4<217::aid-bdd177>3.0.co;2-6. Biopharm Drug Dispos. 1999. PMID: 10440797
-
A Mechanism-Based Population Pharmacokinetics Model of Erythropoietin in Premature Infants and Healthy Adults Following Multiple Intravenous Doses.J Clin Pharmacol. 2019 Jun;59(6):835-846. doi: 10.1002/jcph.1368. Epub 2019 Jan 7. J Clin Pharmacol. 2019. PMID: 30618050 Free PMC article.
-
Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.Clin Pharmacokinet. 2007;46(2):159-73. doi: 10.2165/00003088-200746020-00004. Clin Pharmacokinet. 2007. PMID: 17253886
-
Aspects of theophylline clearance in children.Anaesth Intensive Care. 1997 Oct;25(5):497-501. doi: 10.1177/0310057X9702500508. Anaesth Intensive Care. 1997. PMID: 9352762 Review.
-
Nonlinear pharmacokinetics: clinical Implications.Clin Pharmacokinet. 1991 Jun;20(6):429-46. doi: 10.2165/00003088-199120060-00001. Clin Pharmacokinet. 1991. PMID: 2044328 Review.
Cited by
-
The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep.Pharm Res. 2006 Sep;23(9):2060-6. doi: 10.1007/s11095-006-9064-8. Epub 2006 Aug 9. Pharm Res. 2006. PMID: 16951999
-
Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.Drugs. 2004;64(5):499-509. doi: 10.2165/00003495-200464050-00004. Drugs. 2004. PMID: 14977387 Review.
-
Change in erythropoietin pharmacokinetics following hematopoietic transplantation.Clin Pharmacol Ther. 2007 Jun;81(6):873-9. doi: 10.1038/sj.clpt.6100165. Epub 2007 Apr 11. Clin Pharmacol Ther. 2007. PMID: 17429351 Free PMC article. Clinical Trial.
-
Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.Clin Pharmacokinet. 2013 Dec;52(12):1063-83. doi: 10.1007/s40262-013-0098-x. Clin Pharmacokinet. 2013. PMID: 23912564 Review.
-
Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage.Clin Pharmacokinet. 2004;43(1):57-70. doi: 10.2165/00003088-200443010-00004. Clin Pharmacokinet. 2004. PMID: 14715051 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
